News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Clovis PARP drug gets fast US review in new ovarian cancer u... Impressed by survival data, FDA hastens review in expanded patient group
News Tesaro gets European approval on Zejula, set to challenge AZ Tesaro's PARP drug approved in wider ovarian cancer population
News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News Trump tax reform uncertainty puts biotech M&A on hold Tesaro and Puma are potential takeover targets
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.